Literature DB >> 19348561

Baculovirus vector as a delivery vehicle for influenza vaccines.

Fang He1, Selvaraj Madhan, Jimmy Kwang.   

Abstract

The baculovirus vector has emerged as an efficient delivery vehicle for influenza vaccines. In addition to the ease and safety in expeditious production, recent improvements in baculovirus engineering to display foreign proteins on the surface and to express transgenes with suitable promoters in various cell lines have become milestones in the development of the baculovirus expression system. Surface-displayed and shuttle promoter-mediated baculovirus vaccines for influenza present advantages in immunogenicity and safety, as studied in several animal models. A variety of strategies, including the modification of envelope proteins for surface display, the selection of novel promoters for in vivo transductions and advancements in downstream processing, aid the improvement of baculovirus-based influenza vaccines and represent progress toward next-generation vaccines for influenza.

Mesh:

Substances:

Year:  2009        PMID: 19348561     DOI: 10.1586/erv.09.2

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  12 in total

1.  A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.

Authors:  Yunrui Tan; Qingyong Ng; Qiang Jia; Jimmy Kwang; Fang He
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

2.  Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.

Authors:  Mookkan Prabakaran; Selvaraj Madhan; Nayana Prabhu; Jia Qiang; Jimmy Kwang
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

3.  Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8+ T-cell immunity against respiratory syncytial virus infection.

Authors:  Jeong-Yoon Lee; Jun Chang
Journal:  J Microbiol       Date:  2017-10-27       Impact factor: 3.422

4.  Purification of functional baculovirus particles from silkworm larval hemolymph and their use as nanoparticles for the detection of human prorenin receptor (PRR) binding.

Authors:  Tatsuya Kato; Fumiaki Suzuki; Enoch Y Park
Journal:  BMC Biotechnol       Date:  2011-06-02       Impact factor: 2.563

5.  Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice.

Authors:  Tao Meng; Annasaheb B Kolpe; Tanja K Kiener; Vincent T K Chow; Jimmy Kwang
Journal:  PLoS One       Date:  2011-07-01       Impact factor: 3.240

Review 6.  Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.

Authors:  Marine L B Hillaire; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Biomed Biotechnol       Date:  2011-10-05

Review 7.  Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head.

Authors:  Lidewij C M Wiersma; Guus F Rimmelzwaan; Rory D de Vries
Journal:  Vaccines (Basel)       Date:  2015-03-26

8.  Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.

Authors:  Li Zhang; Jing Lu; Yin Chen; Fengjuan Shi; Huiyan Yu; Chao Huang; Lunbiao Cui; Zhiyang Shi; Yongjun Jiao; Yuemei Hu
Journal:  Viruses       Date:  2015-08-04       Impact factor: 5.048

9.  One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.

Authors:  Miriam Klausberger; Monika Wilde; Dieter Palmberger; Rong Hai; Randy A Albrecht; Irina Margine; Ariana Hirsh; Adolfo García-Sastre; Reingard Grabherr; Florian Krammer
Journal:  Vaccine       Date:  2013-11-18       Impact factor: 3.641

10.  Characterization of the immune responses elicited by baculovirus-based vector vaccines against influenza virus hemagglutinin.

Authors:  Zhi-peng Hu; Juan Yin; Yuan-yuan Zhang; Shu-ya Jia; Zuo-jia Chen; Jiang Zhong
Journal:  Acta Pharmacol Sin       Date:  2012-05-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.